Rapport Therapeutics’ (NASDAQ:RAPP – Get Free Report) lock-up period is set to expire on Wednesday, December 4th. Rapport Therapeutics had issued 8,000,000 shares in its initial public offering on June 7th. The total size of the offering was $136,000,000 based on an initial share price of $17.00. After the expiration of Rapport Therapeutics’ lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
Rapport Therapeutics Trading Up 0.0 %
Shares of RAPP opened at $22.34 on Wednesday. Rapport Therapeutics has a 52 week low of $16.55 and a 52 week high of $29.74. The stock has a 50 day moving average of $23.01.
Institutional Investors Weigh In On Rapport Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC boosted its stake in shares of Rapport Therapeutics by 36.8% in the 3rd quarter. Barclays PLC now owns 12,863 shares of the company’s stock worth $264,000 after buying an additional 3,463 shares during the last quarter. Geode Capital Management LLC purchased a new position in Rapport Therapeutics in the third quarter worth about $4,133,000. State Street Corp bought a new stake in shares of Rapport Therapeutics during the 3rd quarter valued at about $1,189,000. Maven Securities LTD bought a new position in shares of Rapport Therapeutics in the 3rd quarter worth approximately $613,000. Finally, Eventide Asset Management LLC boosted its holdings in shares of Rapport Therapeutics by 120.8% in the third quarter. Eventide Asset Management LLC now owns 110,401 shares of the company’s stock worth $2,261,000 after buying an additional 60,401 shares during the last quarter.
Rapport Therapeutics Company Profile
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Articles
- Five stocks we like better than Rapport Therapeutics
- How to Find Undervalued Stocks
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- What is the Nasdaq? Complete Overview with History
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- What Makes a Stock a Good Dividend Stock?
- Why Amazon Shares May Never Trade Below $200 Again
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
